Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 54-59    DOI: 10.31083/j.ejgo.2020.01.4758
Original Research Previous articles | Next articles
High-dose-rate intracavitary brachytherapy for non-palpable and non-visible recurrent vaginal stump tumors after hysterectomy
M. Sakaguchi1, *(), T. Maebayashi1, T. Aizawa1, N. Ishibashi1, T. Saito2
1 Department of Radiology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan
2 Sonodakai Radiation Oncology Clinic, Adachi-ku, Tokyo, Japan
Download:  PDF(1226KB)  ( 269 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: The purpose of this study was to evaluate patients who were treated with high-dose-rate (HDR) intracavitary brachytherapy for non-palpable and non-visible recurrent vaginal stump that occurred after hysterectomy. Materials and Methods: This retrospective study included 11 patients aged 52-81 (median, 61) years. The HDR brachytherapy was performed using a remote after-loading system (RALS). The dose per fraction was planned at mainly 4 Gy/fraction, twice per week, for a total of 32 Gy. Results: CR and PR were diagnosed on cytology or visual examination in nine (82%) patients and in one (9%) patient, respectively. SD was noted in one (9%) patient. Isolated stump recurrence developed in five patients and the three-year LC rate was 53%. There was no severe acute and late toxicity. Conclusion: Local salvage is possible with a three-year LC rate of 53% with regard to non-palpable and non-visible limited vaginal recurrence of gynecological cancer that responds to HDR brachytherapy (4 Gy/fraction, total 32 Gy).
Key words:  High-dose-rate intracavitary brachytherapy      Recurrent vaginal stump      Hysterectomy      Remote after-loading system      Gynecological cancer     
Published:  15 February 2020     
*Corresponding Author(s):  M. SAKAGUCHI     E-mail:  sakaguchi.masakuni@nihon-u.ac.jp

Cite this article: 

M. Sakaguchi, T. Maebayashi, T. Aizawa, N. Ishibashi, T. Saito. High-dose-rate intracavitary brachytherapy for non-palpable and non-visible recurrent vaginal stump tumors after hysterectomy. European Journal of Gynaecological Oncology, 2020, 41(1): 54-59.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.4758     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/54

[1] Youngsun Kim, Sungkyoung Moon, Kiyong Na. Metastatic mesonephric adenocarcinoma of unknown origin after hysterectomy: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 828-832.
[2] John P. Micha, Howard D. Epstein, Michael C. Roossin, Randy Bohart, Mark A. Rettenmaier, Bram H. Goldstein. Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 797-801.
[3] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[4] Zeyneb Bakacak, Mustafa Kaplanoğlu, Murat Bakacak, Tuncay çelik. Demodex folliculorum mite infestation in gynecological cancers: A case control study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 583-586.
[5] Terumi Tanigawa, Maki Matoda, Yoichi Aoki, Hidetaka Nomura, Sanshiro Okamoto, Kohei Omatsu, Hiroyuki Kanao, Nobuhiro Takeshima. A case of recurrent smooth muscle tumor of uncertain malignant potential with abdominal dissemination after morcellation[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 648-650.
[6] Mustafa Ayhan Ekici, Ali Can Onal, Caglar Cetin. Likelihood of incidental finding of gynecological cancer in women undergoing hysterectomy for benign indications[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 402-407.
[7] X.F. Xu, Q. Li, A.Y. Dai, H.J. Zhou, J.X. Ling. Neoadjuvant chemotherapy followed by radical surgery for Stage IB2 cervical cancer in pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 489-491.
[8] I. Ferreira, C. Estevinho, A. Torgal, C. Carrapatoso, F. Costa. Should we search for high-risk HPV in vaginal vault Pap smear after hysterectomy due to CIN2+?[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 157-162.
[9] X. Zhang, Y. Fu, X. Zhang, J. Ding, K. Hua. The effect of transcutaneous electrical stimulation treatment in combination with intraoperative nerve staining on sexual function after radical hysterectomy: a pilot study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 188-191.
[10] H.Ç. Özcan, Ö. Balat, M.G. Uğur, S. Sucu, N.B. Tepe, Ö.K. Karuserci̇, Z. Bozdağ. Extraperitoneal pelvic lymph node dissection with laparotomy in occult invasive cervical cancer found after a simple hysterectomy[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 982-987.
[11] P.-S. Huang, C.-T. Yue, W.-Y. Kao, J.-M. Hwang, H.-W. Kuo, S.-C. Huang. Undifferentiated endometrial sarcoma of the cervix: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1035-1038.
[12] J. Klat, O. Simetka, C. Povysil. Cervical leiomyosarcoma treated by radical laparoscopic approach: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1093-1095.
[13] Yangyang Shi, Yongyun Shi, Dabao Wu. A case of placental site trophoblastic tumor and a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1096-1099.
[14] R. Du, L. Li, S. Ma, X. Tan, S. Zhong, M. Wu. Survival outcomes of Stage IB cervical cancer treated with standard radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 810-814.
[15] J.J. Noh, H. Jung, C.H. Choi. Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 679-683.
No Suggested Reading articles found!